ClinicalTrials.gg
Not yet recruitingNCT07946796SemenGlutideUpdated Nov 18, 2026

Semaglutide Effects on Sperm Concentration in Overweight Infertile Men

A Phase 2 interventional study of Semaglutide (Wegovy®) and Placebo (saline) in Infertility in Overweight Men, sponsored by Copenhagen University Hospital at Herlev. Not yet recruiting at 1 site in Denmark. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionWeight Loss(the registry's first term)UnverifiedIs this wrong?Weight Loss is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Copenhagen University Hospital at Herlev · Phase 2, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

Overweight and obesity are associated with functional hypogonadism and impaired semen quality. Although lifestyle interventions may improve reproductive function, long-term adherence is often challenging. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), increasingly used to treat obesity, have shown promising effects on weight loss, testosterone levels and potentially semen quality through both direct and indirect mechanisms. However, clinical evidence regarding their effects on male fertility remains limited.

The SemenGlutide trial is a randomised, double-blinded, placebo-controlled, single-centre clinical trial investigating whether once-weekly subcutaneous semaglutide improves semen quality in overweight infertile men, compared with placebo.

Read the detailed description

It is estimated that around 10-20 percentage of couples worldwide experience infertility. In up to 30-50 percent of these cases, the male is a significant contributing factor. Very few new treatment modalities are being developed to improve semen quality or sperm function despite the significant male contribution to the infertility problem and the observed global decline in semen quality. While assisted reproductive technology (ART) has improved tremendously, these techniques only focus on treating the female even when the male is the only cause of infertility. While infertility is defined at the couple level, male fertility potential is typically evaluated by routine semen analyses where sperm concentration, sperm motility and morphology are assessed. Men with overweight often struggle with functional hypogonadism and possible direct testicular effects resulting in impaired semen quality. Functional hypogonadism is a potentially reversible condition characterised by mild to moderately low testosterone levels with low-to-normal luteinizing hormone (LH) levels thought to originate from age and/or lifestyle-related comorbidities, including obesity and metabolic syndrome. To maintain normal spermatogenesis, a functioning hypothalamic-pituitary-gonadal (HPG) axis is required. It is known that obesity can affect and impair the HPG axis, however, the mechanism of the proposed potential concomitant impaired semen quality has been discussed regarding inflammation or the direct effect of an impaired HPG-axis, playing the main role. Overweight and obese men have functional or hypogonadotropic hypogonadism phenotype that can lead to reduced semen quality. Lifestyle interventions can be effective, but compliance with these interventions is difficult, and many men fail in the long term. Recent advances in knowledge of the effects of glucagon-like peptide-1 receptor agonists (GLP-1RA) suggest that this class of drugs can improve hypogonadism and maybe also semen quality in overweight and obese men by both direct and indirect effects. GLP-1RAs are being used more frequently, and new roles in non-classical targets are emerging. A recent systematic review and meta-analysis investigating the effect of GLP-1RAs on testosterone in males suffering from overweight/obesity showed that treatment with GLP-1RAs resulted in weight loss, improved testicular function and a possible favourable effect on testosterone and gonadotropins. Considering this, weight loss medication is possibly a favourable tool to use in overweight patients with male infertility irrespective of the presence of obesity. GLP-1RA, Semaglutide, is approved for the management of overweight/obesity in doses up to 2.4 mg and induces substantial weight loss. GLP-1RA administration increases hypothalamic kisspeptin expression and stimulates gonadotropin-releasing hormone (GnRH) secretion in rodent studies. In addition, Semaglutide may have a direct testicular effect that appears to be beneficial, as shown by data from the Division of Translational Endocrinology, Herlev but also a study by Signe Torekovs group showing improved semen quality in men with normal fertility following weight loss and liraglutide treatment.

SemenGlutide is a randomised double-blinded, placebo-controlled, single-center, clinical trial comparing the effects of subcutaneous (s.c.) Semaglutide 2.4 mg once-weekly versus placebo on sperm concentration in overweight infertile men. The study aims to investigate whether semaglutide can improve semen quality in infertile men with a body mass index (BMI) of at least 27 kg/m\^2. The hypothesis is that semaglutide treatment will result in a greater increase in sperm production compared with placebo.

Following confirmation of eligibility and obtained informed consent, participants will be randomised at baseline in a 1.5:1 ratio to receive either semaglutide or placebo. Participants will receive the study medication for self-administration at home throughout the trial, with regular dispensing by trained study personnel. The dose will be gradually titrated to the target dose of 2.4 mg semaglutide or corresponding placebo. A total of 150 men will be enrolled, with at least 120 expected to complete the trial. This sample size will provide 80 percent power to detect a 65 percent greater increase in sperm concentration in the semaglutide group compared with placebo at day 200, using a significance level of 5 percent.

Safety is evaluated throughout the study using repeated clinical assessments, laboratory monitoring, and systematic recording of adverse events. All side effects will be closely monitored and reported. The study is approved by the regional ethical committee, conducted in compliance with The Declaration of Helsinki and monitored by the Good Clinical Practice unit of Copenhagen University Hospitals.

02

Conditions studied

  • Infertility in Overweight Men

Keywords

  • GLP-1RA
  • Semaglutide
  • Glucagon-like peptide-1 receptor agonists
  • Weight loss
  • Metabolic health
  • Male reproductive health
  • Male fertility
  • Spermatogenesis
  • Semen quality
  • Semen parameters
  • Gonadal function
  • Hypothalamic-pituitary-gonadal axis
  • Metabolic syndrome
  • Obesity
  • Reproductive endocrinology
  • Sperm concentration
  • Overweight
  • Infertility
  • Functional hypogonadism
03

In context

Weight Loss Unverified

1,820 studies on the registry are indexed under Weight Loss; 298 are open to participants now.

This study's planned enrollment of 150 is above the median of 80 across 1,566 interventional studies indexed under Weight Loss.

Browse Weight Loss studies →

Lead sponsor

Copenhagen University Hospital at Herlev is the lead sponsor of 78 studies on the registry; 10 are open to participants now.

Compared within Weight Loss, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.
  • Men 18 to 60 years of age (both inclusive) at the time of signing informed consent.
  • Infertile men with at least one altered semen parameter (Sperm concentration \< 16 million/mL, or percentage of motile spermatozoa \< 42%, or percentage of morphologically normal spermatozoa \< 4%)
  • (BMI) ≥ 27 kg/m\^2

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Total sperm count >80 million
  • Sperm concentration \< 1 million/mL
  • > 50 kg/m\^2
  • Estimated (eGFR) \<45 ml/min/1.73 m\^2
  • Known chromosomal aberrations (except minor Y-chromosome deletions)
  • Detected cystic fibrosis transmembrane conductance regulator (CFTR) mutation
  • Treatment with glucagon-like peptide-1-receptor-agonist (GLP-1RA) 6 months prior to inclusion
  • Any disorder which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol
  • Obesity related to endocrinologic disorders (e.g., Cushing's syndrome)
  • Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: Herbal products and non-routine vitamins , Insulin, medication that may cause weight gain (including systemic , tricyclic antidepressants, and atypical antipsychotics), orlistat, zonisamide, topiramate, phentermine, lorcaserin, bupropion, naltrexone or other weight loss drugs. Blood pressure and lipid lowering agents (e.g., statins) drugs are allowed if treatment has been stable for ≥ 1 month prior to screening at visit 0.
  • History of pancreatitis (acute or chronic)
  • Daily use of morphine
  • Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
  • History of bariatric surgery
  • Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator's opinion could interfere with the results of the trial
  • Inability or unwillingness to perform self-injection at the screening visit (with a placebo test pen)
  • Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
  • Dysregulated type 2 diabetes judged by the investigators
  • Serum follicle-stimulating hormone (FSH) \<2 IU/L
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Semaglutide

    Semaglutide 2.4 mg administered subcutaneously once weekly

    Drug: Semaglutide (Wegovy®)

  • Placebo comparator
    Placebo

    Saline administered subcutaneously once weekly

    Drug: Placebo (saline)

Interventions

  • Titration algorithms are used in order to ensure participants receive optimal treatment with minimal side-effects. Patients will recieve full dosage of 2.4mg a week from week 16 to week 43.

  • DrugPlacebo (saline)

    Titration algorithms similar to those used in the intervention group will be applied to maintain blinding. Participants will receive the full target dose once weekly from week 16 to week 43.

06

What researchers measure

Primary outcomes

  1. Difference in sperm concentration or total sperm count on day 200

    Difference in sperm production evaluated by sperm concentration (millions/mL) or total sperm count (millions) measured by semen analysis.

    Time frame: From baseline to day 200

Secondary outcomes

  1. Difference in sperm concentration from baseline to day 300

    Difference in sperm concentration (millions/mL) evaluated by semen analysis

    Time frame: From baseline to day 300

  2. Differences and changes in DNA fragmentation index (%) from baseline to day 300

    Time frame: From baseline to day 200 and 300

  3. Changes in sperm parameters from baseline to day 300

    Measured by number (millions)

    Time frame: From baseline to day 100, 200 and 300

  4. Differences in sperm production from baseline to day 300

    Sperm concentration (million/mL) evaluated by the automated CASA SCA (Microptic) system

    Time frame: From baseline to day 200 and 300

  5. Differences in body mass index (BMI) from baseline to day 300

    Weight (kg) and height (cm) is measured at each visit during the trial, and will be combined to report BMI

    Time frame: From baseline to day 100, 200 and 300

  6. Differences in total body fat percentage (%) from baseline to day 300

    Evaluated by dual-energy x-ray absorptiometry (DXA) scan

    Time frame: From baseline to day 300

  7. Differences in bone mineral density (BMD) g/cm^2 from baseline to day 300

    Evaluated by DXA scan

    Time frame: From baseline to day 300

  8. Changes in subjective symptoms of androgen deficiency from baseline to day 300

    Assessed using Androgen Deficiency in the Aging Male questionnaire (ADAM). The summation of the responses yields a total ADAM score between 10 and 50, with 10 being most symptomatic and 50 being least symptomatic.

    Time frame: From baseline to day 300

  9. Changes in male sexual function from baseline to day 300

    Assessed using The International Index of Erectile Function questionnaire (IIEF-5). The possible scores for the IIEF-5 range from 5 to 25, and erectile dysfunction (ED) is classified into five categories based on the scores: severe (5-7), moderate (8-11), mild to moderate (12-16), mild (17-21), and no ED (22-25).

    Time frame: From baseline to day 300

  10. Changes in total testosterone (nmol/L) and free testosterone (nmol/L) from baseline to day 300

    Measured by blood sample

    Time frame: From baseline to day 100, day 200 and day 300

  11. Differences in luteinizing hormone (IU/L) and follicel stimulating hormone (IU/L) from baseline to day 300

    Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  12. Differences in HbA1c from baseline to day 300

    Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  13. Differences in lipid profile from baseline to day 300

    Differences in total cholesterol (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L) and triglycerides (mmol/L). Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  14. Changes in sperm parameters from baseline to day 300

    Measured by motility (%) by semen analysis

    Time frame: From baseline to day 100, 200 and 300

  15. Changes in sperm parameters from baseline to day 300

    Measured by morphology (%) by semen analysis

    Time frame: From baseline to day 100, 200 and 300

  16. Differences in sperm production from baseline to day 300

    Total sperm count (million) evaluated by the automated CASA SCA (Microptic) system

    Time frame: From baseline to day 200 and 300

  17. Differences in sperm production from baseline to day 300

    Total motile sperm (%) evaluated by the automated CASA SCA (Microptic) system

    Time frame: From baseline to day 200 and 300

  18. Differences in total muscle mass (kg) from baseline to day 300

    Evaluated by DXA scan

    Time frame: From baseline to day 300

  19. Differences in trabecular bone score (TBS) from baseline to day 300

    Evaluated by DXA scan. A normal TBS is defined as \>1.350 (no units) where TBS bewteen 1.200 and 1.350 is defined as partially degraded bone.

    Time frame: From baseline to day 300

  20. Differences in sex hormone binding globulin (SHBG) (nmol/L) from baseline to day 300

    Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  21. Differences in Anti-Müllerian Hormone (AMH) (pmol/L) from baseline to day 300

    Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  22. Differences in inhibin B (ng/L) from baseline to day 300

    Measured by bloodsample.

    Time frame: From baseline to day 100, day 200 and day 300

  23. Differences in HOMA-IR from baseline to day 300

    HOMA-IR will be calculated as follows: (plasma insulin (µIU/mL) × plasma glucose (mg/dL)) / 405 = HOMA-IR. Values \<1.0 indicate optimal insulin sensitivity, 1.0-1.9 indicate mild insulin resistance, 2.0-2.9 indicate moderate insulin resistance, and \>3.0 indicate significant insulin resistance.

    Time frame: From baseline to day 100, day 200 and day 300

Other outcomes

  1. Changes in circulating markers of bone resorption and formation from baseline to day 300

    Changes in procollagen type I N-terminal propeptide (PINP), Receptor Activator of Nuclear Factor κB Ligand (RANKL), Osteoprotegerin (OPG) and C-terminal telopeptide of type I collagen (CTX) measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  2. Changes in calcium homeostasis and spoturine from baseline to day 300

    Measured by serum (albumin, calcium, phosphate) and urine (calcium, iron, ferritin, zinc, magnesium, phosphate, sodium and creatinine)

    Time frame: From baseline to day 100, day 200 and day 300

  3. Change in mineral homeostasis from baseline to day 300

    Changes in serum iron, ferritin, hepcidin, transferrin, magnesium, zinc, measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  4. Changes in calciotropic hormones from baseline to day 300

    Changes in serum 25OHD, parathyroid hormone (PTH), Klotho and fibroblast growth factor 23 (FGF23), measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  5. Changes in serum vitamin D metabolites from baseline to day 300

    Changes in serum cholecalciferol, 25OHD, 24,25OHD 1,25OHD and cholecalciferol/25OHD ratio, 25OHD/24,25OHD ratio, measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  6. Changes in androstenedione, progesterone, cortisol, cortisone and dehydroepiandrosterone sulfate (DHEAS) from baseline to day 300

    Measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  7. Changes in 11-oxy-androgens and androgens from the alternative pathway from baseline to day 300

    Measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  8. Changes in thyroid stimulating hormone (TSH), T3, T4, CBG, TBG, INSL-3, Prolactin from baseline to day 300

    Measured by bloodsample

    Time frame: From baseline to day 100, day 200 and day 300

  9. Changes in seminal fluid of minerals and hormones from baseline to day 300

    Seminal fluid

    Time frame: From baseline to day 100, day 200 and day 300

07

Study locations

1 site
08

References and documents

Publications

  • Andersen E, Juhl CR, Kjoller ET, Lundgren JR, Janus C, Dehestani Y, Saupstad M, Ingerslev LR, Duun OM, Jensen SBK, Holst JJ, Stallknecht BM, Madsbad S, Torekov SS, Barres R. Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial. Hum Reprod. 2022 Jun 30;37(7):1414-1422. doi: 10.1093/humrep/deac096. PubMed 35580859 ↗
  • Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest. 1998 Mar 15;101(6):1334-41. doi: 10.1172/JCI610. PubMed 9502775 ↗
  • Oride A, Kanasaki H, Mijiddorj T, Sukhbaatar U, Hara T, Tumurbaatar T, Kyo S. GLP-1 increases Kiss-1 mRNA expression in kisspeptin-expressing neuronal cells. Biol Reprod. 2017 Aug 1;97(2):240-248. doi: 10.1093/biolre/iox087. PubMed 29044434 ↗
  • Salvio G, Ciarloni A, Ambo N, Bordoni M, Perrone M, Rossi S, Balercia G. Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis. Andrology. 2025 Nov;13(8):2022-2034. doi: 10.1111/andr.70022. Epub 2025 Mar 19. PubMed 40105090 ↗
  • Spaziani M, Carlomagno F, Tarantino C, Angelini F, Vincenzi L, Gianfrilli D. New perspectives in functional hypogonadotropic hypogonadism: beyond late onset hypogonadism. Front Endocrinol (Lausanne). 2023 Jun 29;14:1184530. doi: 10.3389/fendo.2023.1184530. eCollection 2023. PubMed 37455902 ↗
  • Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for decreasing quality of semen during past 50 years. BMJ. 1992 Sep 12;305(6854):609-13. doi: 10.1136/bmj.305.6854.609. PubMed 1393072 ↗
  • Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. Reprod Biol Endocrinol. 2015 Apr 26;13:37. doi: 10.1186/s12958-015-0032-1. PubMed 25928197 ↗
  • Thonneau P, Marchand S, Tallec A, Ferial ML, Ducot B, Lansac J, Lopes P, Tabaste JM, Spira A. Incidence and main causes of infertility in a resident population (1,850,000) of three French regions (1988-1989). Hum Reprod. 1991 Jul;6(6):811-6. doi: 10.1093/oxfordjournals.humrep.a137433. PubMed 1757519 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.

Of 44 phase 2 interventional studies under Weight Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartEst.
Jan 2027
Primary completionEst.
Jun 2029
CompletionEst.
Oct 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946796
Lead sponsor
Copenhagen University Hospital at Herlev
Responsible party
Martin Blomberg Jensen (Professor, MD., DMSC, andrologist, Copenhagen University Hospital at Herlev) — Principal investigator
First posted
Nov 18, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Martin Blomberg Jensen, D.M.Sc
Contact
martin.blomberg.jensen@regionh.dk
+45 38 68 63 64
Nanna Gadeberg, M.D.
Contact
nanna.gadeberg.01@regionh.dk
+45 38 68 63 64

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion